CN114306506A - Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof - Google Patents
Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof Download PDFInfo
- Publication number
- CN114306506A CN114306506A CN202111664608.0A CN202111664608A CN114306506A CN 114306506 A CN114306506 A CN 114306506A CN 202111664608 A CN202111664608 A CN 202111664608A CN 114306506 A CN114306506 A CN 114306506A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- preparation
- compound composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 230000036039 immunity Effects 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 title abstract description 26
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 19
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 18
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 18
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 18
- 235000006533 astragalus Nutrition 0.000 claims abstract description 18
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 17
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 17
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 17
- 244000197580 Poria cocos Species 0.000 claims abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims abstract description 15
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 14
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 5
- 241001061264 Astragalus Species 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 18
- 206010057249 Phagocytosis Diseases 0.000 description 15
- 230000008782 phagocytosis Effects 0.000 description 15
- 241000229143 Hippophae Species 0.000 description 14
- 239000013642 negative control Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 241000628997 Flos Species 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 8
- 239000003228 hemolysin Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000005951 type IV hypersensitivity Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000248557 Ophiopogon japonicus Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 101100219682 Mus musculus Cavin3 gene Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound composition with an immunity enhancing effect and a preparation method thereof, wherein the composition is prepared from 10-40 parts of astragalus membranaceus, 5-20 parts of wolfberry fruits, 5-20 parts of radix ophiopogonis, 1-15 parts of schisandra chinensis, 5-20 parts of poria cocos, 2-15 parts of angelica sinensis, 2-20 parts of sea buckthorns and 5-20 parts of chrysanthemum morifolium. According to the theory of traditional Chinese medicine and pharmacy, the eight medicines are selected for compatibility and use in combination with the characteristics of human body functions and the like, so that the whole formula has the effects of tonifying qi and blood, invigorating spleen and nourishing liver, regulating yin and yang, strengthening body resistance and reinforcing vitality, and enhancing the immunity of the human body, has mild effect, and is particularly suitable for the elderly or people with low immunity. In addition, the raw materials of the traditional Chinese medicine are both medicinal and edible products, and are safe and effective.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine compound composition with an immunity enhancing effect and application thereof.
Background
Immunity refers to the physiological function of the body's immune system that recognizes "good oneself" and "impaired oneself" components and rejects "impaired oneself". The traditional Chinese medicine considers that the occurrence and development of immune diseases are mainly related to congenital factors and acquired factors, wherein the congenital factors comprise congenital deficiency, and the acquired factors comprise external six excesses, internal five pathogens, nutrition and defense disorders, qi-blood disharmony, viscera dysfunction and other factors which are closely related. The rhythm of the current social life is accelerated, the competitive pressure is increased day by day, and the irregular diet and work and rest are adopted, so that the organism is in an unbalanced sub-health state, the immunity is reduced, the incidence rate of other diseases is increased, the organism is difficult to recover, the immunity is reduced repeatedly, and a vicious circle is formed.
Most of western medicines capable of improving immunity in the market aim at certain immune diseases, and the side effects are obvious; most of health-care foods capable of improving immunity appear in the forms of nutrition bars, biscuits, soft sweets, solid beverages, wine and tea leaves, related products, dairy products, convenient foods and the like, or are high in price or insignificant in effect, and the like.
Most of the Chinese herbal medicines have little or no toxic and side effects. People pay high attention to the food safety problem and form a consumption concept of 'green and pollution-free'. Therefore, the research and development of green and efficient traditional Chinese medicine immunopotentiators are urgent requirements for the development of times and inevitable development trends, and have very important practical significance. As a component of traditional Chinese medicine, the traditional Chinese medicine has an important regulating effect on the body immunity. According to the theory of traditional Chinese medicine, various traditional Chinese medicines in the traditional Chinese medicine formula can act on the body independently or synergistically in a multi-layer, multi-path and multi-target manner, identify oneself and eliminate the ingredients except the oneself, thereby maintaining the stability of the internal environment of the body and improving the immunity of the body. And most of the traditional Chinese medicines have low toxic and side effects, lasting curative effect and guaranteed safety and treatment effect.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to overcome the defects of the technology and provide the traditional Chinese medicine compound composition which adopts medicinal and edible raw materials, has good enhancement of the immunity of the organism, small toxic and side effects and safe clinical medication through scientific proportioning.
The technical scheme is as follows: in order to achieve the above purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine compound composition with the function of enhancing the immunity of the organism is prepared from the following raw materials in parts by weight:
10-40 parts of astragalus membranaceus, 5-20 parts of wolfberry fruits, 5-20 parts of radix ophiopogonis, 1-15 parts of schisandra chinensis, 5-20 parts of poria cocos, 2-15 parts of angelica sinensis, 2-20 parts of sea buckthorn and 5-20 parts of chrysanthemum morifolium.
As a preferred scheme, the traditional Chinese medicine compound composition with the effect of enhancing the immunity of the organism is prepared from the following raw materials in parts by weight:
20-30 parts of astragalus membranaceus, 10-15 parts of wolfberry fruits, 10-15 parts of radix ophiopogonis, 5-10 parts of schisandra chinensis, 10-15 parts of poria cocos, 4-10 parts of angelica sinensis, 7-15 parts of sea buckthorn and 10-15 parts of chrysanthemum morifolium.
As a preferable scheme, the traditional Chinese medicine compound composition for enhancing immunity is prepared from the following raw materials in parts by weight:
40 parts of astragalus membranaceus, 20 parts of wolfberry fruit, 20 parts of radix ophiopogonis, 10 parts of schisandra chinensis, 20 parts of poria cocos, 8 parts of angelica sinensis, 14 parts of sea buckthorn and 20 parts of chrysanthemum morifolium.
As a preferable scheme, the traditional Chinese medicine compound composition for enhancing immunity is prepared from the following raw materials in parts by weight:
20 parts of astragalus membranaceus, 10 parts of wolfberry fruit, 10 parts of radix ophiopogonis, 5 parts of schisandra chinensis, 10 parts of poria cocos, 4 parts of angelica sinensis, 7 parts of sea buckthorn and 10 parts of chrysanthemum morifolium.
As a preferable scheme, the traditional Chinese medicine compound composition for enhancing immunity is prepared from the following raw materials in parts by weight:
10 parts of astragalus membranaceus, 5 parts of wolfberry fruit, 5 parts of radix ophiopogonis, 1 part of schisandra chinensis, 5 parts of poria cocos, 4 parts of angelica sinensis, 5 parts of sea buckthorn and 5 parts of chrysanthemum morifolium.
The traditional Chinese medicine compound composition with the effect of enhancing immunity is prepared into an oral preparation or an external preparation by the traditional Chinese medicine compound composition and a pharmaceutically acceptable carrier, and comprises tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, buccal tablets, chewable tablets, hard capsules, soft capsules, granules, pills, powder, dropping pills, oral liquid preparations, sprays, gels, ointments, cataplasms, emplastrum, liniments, lotions and film coatings.
The traditional Chinese medicine compound composition provided by the invention has a good effect of enhancing immunity, and can be used for preparing an auxiliary effect for treating other diseases caused by low immunity, such as a sub-health state or a susceptible fatigue state or an application in health care products.
The invention combines the technical characteristics of human body under the guidance of the traditional Chinese medicine theory, selects 8 medicines of astragalus, angelica, dwarf lilyturf tuber, Chinese magnoliavine fruit, medlar, chrysanthemum, tuckahoe, sea backthern and the like for compatibility, and determines the dosage of each medicinal material through the relationship between the functional components and the functions, so that the components have synergistic action. The formula is prepared by combining astragalus root, radix angelicae sinensis and radix angelicae sinensis, and has the effects of tonifying spleen and qi, nourishing blood and activating blood circulation. Ophiopogon root, radix Ophiopogonis has the effect of nourishing yin to promote the production of body fluid, Schisandra chinensis has the effect of nourishing yin to arrest sweating, tonifying qi to promote the production of body fluid, and recovering yin fluid. Wolfberry fruit, fructus Lycii, flos Chrysanthemi, fructus Lycii, flos Chrysanthemi, fructus Lycii, flos Chrysanthemi, fructus Lycii, flos Chrysanthemi, fructus Lycii, and flos Chrysanthemi. Poria strengthens spleen, promotes diuresis, calms heart, and sea buckthorn tonifies spleen, benefits qi and promotes digestion, and both are compatible to nourish heart and spleen. The medicines in the formula are both medicinal and edible, have mild medicine property, are most suitable for the old to take for a long time, slowly take the effect and prolong the life. Polysaccharide components of 8 Chinese medicaments in the formula have the function of enhancing immunity, and in addition, astragalus saponin, chrysanthemum morifolium total flavone, astragalus total flavone, sea buckthorn total flavone and schisandra lignan also have the function of enhancing immunity; the high isoflavone of radix Ophiopogonis has anti-tumor effect, and chlorogenic acid of flos Chrysanthemi has anti-tumor and immunity enhancing effects.
The traditional Chinese medicine compound composition formed by the whole formula has the effects of tonifying qi and blood, invigorating spleen and nourishing liver, regulating yin and yang, strengthening body resistance and reinforcing the immunity of a human body, has mild effect and slow-release effect, and is particularly suitable for the aged or people with low immunity. Moreover, all the traditional Chinese medicines in the invention are medicinal and edible products, and are safe and effective.
The preparation method of the traditional Chinese medicine compound composition provided by the invention comprises the following steps:
taking radix astragali, angelica, radix ophiopogonis, schisandra chinensis, wolfberry, chrysanthemum, poria cocos and sea buckthorn according to parts by weight, adding 5-15 times of water or 10-70% ethanol of traditional Chinese medicines into the mixture, extracting for 1-3 times, 0.5-2 hours each time, combining extracting solutions, concentrating under reduced pressure or normal pressure, and drying in vacuum or spray to obtain extract dry powder.
The traditional Chinese medicine compound composition provided by the invention can be conveniently prepared into various dosage forms of medicines with pharmaceutically acceptable carriers, and is convenient for clinical medication.
Drawings
FIG. 1 mouse carbon clearance phagocytosis index for each dose group.
FIG. 2 shows the percentage of phagocytosis of chicken erythrocytes by macrophages in mice of each dose group.
FIG. 3 is a graph showing the phagocytosis index of chicken erythrocytes by macrophages in mice of each dose group.
Detailed Description
In order that the invention may be more clearly understood, reference will now be made in detail to the following examples. It is to be understood that the specific material ratios, process conditions and results thereof described in the examples are illustrative only and are not intended to limit the invention as detailed in the claims.
Example 1
1. A traditional Chinese medicine compound composition with the effect of enhancing the immunity of organisms is prepared from the following raw materials in parts by weight:
40 parts of astragalus membranaceus, 20 parts of wolfberry fruit, 20 parts of radix ophiopogonis, 10 parts of schisandra chinensis, 20 parts of poria cocos, 8 parts of angelica sinensis, 14 parts of sea buckthorn and 20 parts of chrysanthemum morifolium.
2. The preparation process comprises the following steps: taking 40 parts of astragalus membranaceus, 20 parts of wolfberry fruit, 20 parts of radix ophiopogonis, 10 parts of schisandra chinensis, 20 parts of poria cocos, 8 parts of angelica sinensis, 14 parts of sea buckthorn and 20 parts of chrysanthemum morifolium ramat, adding ethanol with the volume of 12 times of the weight of the medicinal materials and the concentration of 70% into the medicinal materials, extracting for 2 times and 2 hours each time, combining extracting solutions, carrying out reduced pressure concentration at 60 ℃ to obtain a concentrated solution, and carrying out vacuum drying at 70 ℃ to obtain the traditional Chinese medicine composition. Wherein, the sample components mainly comprise 20 percent of total polysaccharide, 50 percent of total flavone and 7 percent of total phenolic acid.
3. Pharmacological experiments:
3.1 materials and methods
3.1.1 drugs and materials
The compound traditional Chinese medicine composition prepared in the embodiment 1.
3.1.2 animals: the SPF grade C57BL/6J mice are 240 and have the weight of 18-22 g.
3.1.3 raising conditions: the mice are raised in a barrier system with the temperature of 20-24 ℃ and the humidity of 40% -60%, and are fed with food and water freely.
3.1.4 dose design: the traditional Chinese medicine compound composition with the effect of enhancing immunity, which is prepared in example 1, is designed into three dosage groups, namely 1.89g/Kg.BW, 3.78g/Kg.BW and 7.56g/Kg.BW, wherein the dosages of the three dosage groups are respectively equal to 20 times, 10 times and 5 times of the recommended dosage of a human body, a normal administration group is also designed to be equal to 10 times of the recommended dosage of the human body, a model control group, hydrocortisone is subjected to gastric lavage molding according to 1.7 mg/patient, and a negative control group (distilled water) is designed.
3.1.5 sample preparation: the traditional Chinese medicine compound composition with the immunity enhancing effect, which is prepared in the embodiment 1, is added with taurine powder in a corresponding proportion, and distilled water is added to be uniformly mixed to prepare suspensions with the concentration of 100% and 50% for standby.
3.1.6 methods of experiment: SPF grade C57BL/6J mice were divided into 4 experimental groups by weight, each group was divided into 6 groups by using 60 mice randomly, each experimental group was provided with three dose groups (1 medium dose group, 1 high dose group, 1 low dose group), 1 normal administration dose group without model, 1 model group and 1 negative control group, each group was 10 mice. A first group of mice for determination of Delayed Type Hypersensitivity (DTH), a second group of antibody-producing cells for detection, determination of serum hemolysin, a third group of mice for carbon clearance test and a fourth group of mice for abdominal cavity macrophage phagocytosis of chicken red blood cells test. The tested sample is administrated once a day by intragastric administration according to the dosage, and distilled water with equal volume is administrated to a negative control group, the maximum intragastric administration volume is 4mL/Kg.BW, and the continuous administration lasts for 30 days.
After preventive administration, the model group is continuously administered with hydrocortisone by intragastric administration for 3d, the weight, drinking water, diet and the like are recorded, intragastric administration is continuously carried out according to each dosage group, and the hydrocortisone intragastric administration is carried out once a week to keep the model stable.
3.2 test methods and results:
3.2.1 mouse delayed type allergy (DTH) assay
On the 26 th day of the test sample, the animals were sensitized by intraperitoneal injection of 0.2 mL/mouse of 2% (v/v) SRBC, and the mice were challenged by subcutaneous injection of 20% (v/v) SRBC 20. mu.L/mouse in the left hind paw on the fourth day after sensitization. And the thickness of the same part of the left hind paw of each mouse is measured 24h before and after the attack, the thickness of the same part is measured three times, and the average value is taken. The difference between the thickness of the foot sole before and after the attack is calculated, and the result of each dosage group is compared with the result of the model control group for variance analysis. The results are shown in Table 1.
TABLE 1SRBC induced DTH anterior and posterior toe posterior degree difference table
| Group of | Weight gain (g) | SRBC induced DTH front and back toe back degree difference (mm) |
| Negative control group | 2.21±0.53 | 0.36±0.05* |
| Model control group | 0.67±0.64 | 0.65±0.32 |
| Normal dose group | 1.69±0.55 | 0.25±0.08* |
| Low dose group | 1.02±0.68 | 0.42±0.23 |
| Middle dose group | 1.87±0.46 | 0.26±0.07* |
| High dose group | 1.95±0.59 | 0.23±0.16* |
Note: each dose group represents P <0.05 compared to the model control group.
From the above results, the difference between the model control group and the negative control group is significant (P <0.05), indicating that the modeling is successful; the difference between the medium and high dose groups and the model control group is significant (P <0.05), which indicates that the medium and high dose groups can enhance the mouse response to SBRC-induced DTH.
3.2.2 detection of antibody-producing cells
Intraperitoneal injection of 0.2 mL/mouse SRBC of 2% (v/v), cervical dislocation of immunized mice after 4 days, taking out spleen, placing in a small plate containing Hank's solution, lightly grinding spleen to obtain cell suspension, filtering with 200 mesh screen, centrifuging (1000r/min) for 10min, washing with Hank's solution for 2 times, suspending cells in 5mLRPMI1640 MI culture solution, counting cells, and adjusting cell concentration to 5 × 106one/mL.
Determination of plaques: the surface layer medium (lg agarose plus double distilled water to l00mL) was dissolved by heating,placing into 45-50 deg.C water bath, keeping temperature, mixing with 2 times concentration of Hank's solution with equal amount of pH7.2-7.4, subpackaging into small tubes with 0.5mL each, adding 50 μ L10% SRBC (v/v, prepared with SA buffer solution), 20 μ L spleen cell suspension (5 × 106One per mL), quickly mixing, pouring the mixture on a slide brushed with an agarose thin layer to form a parallel sheet, after the agar is solidified, horizontally buckling the slide on a slide rack, putting the slide rack into a carbon dioxide incubator to incubate for I.5h, then adding complement (l:8) diluted by SA buffer solution into a groove of the slide rack, and counting the number of hemolytic plaques after continuously incubating for I.5h. The results are shown in Table 2.
TABLE 2 hemolytic plaque Table
| Group of | Number of hemolytic plaques (/ 10)5Spleen cell) |
| Negative control group | 97.33±9.63* |
| Model control group | 77.13±9.21 |
| Normal dose group | 135.15±9.07* |
| Low dose group | 121.96±9.30* |
| Middle dose group | 132.12±9.24* |
| High dose group | 153.68±9.15* |
Note: each dose group represents P <0.05 compared to the model control group.
From the above results, the difference between the model control group and the negative control group is significant (P <0.05), indicating that the modeling is successful; compared with the model control group, the difference of each dose group is significant (P < 0.05).
3.2.3 measurement of serum hemolysin
On the 26 th day, each mouse was injected with 0.2mL of 2% SRBC per abdominal cavity, and the eyeball was removed and blood was collected on the fourth day after immunization. The serum was isolated. Diluting the serum by multiple times with normal saline, respectively placing the serum with different dilutions into a micro hemagglutination plate with each hole of 100 μ L, adding 100 μ L of 0.5% (v/v) SRBC suspension, mixing well, placing into a wet flat disc, covering, and incubating at 37 ℃ for 3h for serum hemolysin determination. And counting the hemagglutination degree, and calculating the corresponding antibody product number. The results are shown in Table 3.
TABLE 3 serum hemolysin table
| Group of | Serum hemolysin (antibody accumulation) |
| Negative control group | 39.32±3.23* |
| Model control group | 30.54±2.73 |
| Normal dose group | 45.77±2.55* |
| Low dose group | 41.46±3.81* |
| Middle dose group | 45.68±2.73* |
| High dose group | 48.76±2.67* |
Note: each dose group represents P <0.05 compared to the model control group.
From the above results, the difference between the model control group and the negative control group is significant (P <0.05), indicating that the modeling is successful; compared with the model control group, the difference of each dose group is significant (P < 0.05). Thus, the serum hemolysin level of the mice can be improved by each dosage group.
3.2.4 carbon Clearance test
Mice in each group were injected tail vein with india ink (4.0 fold dilution with normal saline) l0mL/kg. 20 μ L of blood was taken from each mouse through the angular venous plexus at 2min and L0min after the injection of ink, and rapidly added to 2mL of 0.1% sodium carbonate solution and shaken well. A sodium carbonate solution was used as a blank control, and an ultraviolet-visible spectrophotometer was used to measure the Optical Density (OD) value at a wavelength of 600 nm. After the mice were sacrificed, the liver and spleen were removed, and blood stains on the surface of the organs were blotted with filter paper and weighed. Phagocytosis index (a) was calculated according to the formula, and the results are shown in FIG. 1.
The difference was significant (P <0.05) for each dose group compared to the negative control group. The results show that each dosage group of the sample can improve the phagocytosis index of the mouse carbon clearance.
3.2.5 test for phagocytosis of chicken red blood cells by abdominal macrophages of mice
A semi-in vivo method is adopted. Each group of mice was intraperitoneally injected with lmL% (v/v) of chicken red blood cell suspension, sacrificed by cervical dislocation at intervals of 30 minutes, and intraperitoneally injected with 2 mL/mouse of physiological saline. The rat plate lmin is rotated, the abdominal cavity washing liquid lmL is sucked out and evenly dripped on 2 glass slides, the glass slides are placed in an enamel box filled with wet gauze, and the glass slides are incubated for 30min at 37 ℃. After incubation, the cells were rinsed with normal saline, air-dried, fixed with 1:1 acetone methanol solution, stained with 4% (v/v) Giemsa-phosphate buffer, rinsed with distilled water, and air-dried. Observing 100 macrophages under microscope oil microscope, counting the number of macrophages engulfed chicken erythrocyte, the total number of chicken erythrocyte engulfed by macrophages and their digestion degree, and calculating phagocytosis rate and phagocytosis index according to formula, the result is shown in figure 2.
The phagocytosis percentage and the phagocytosis index of chicken erythrocytes phagocytosed by macrophages of mice in each dose group are different from those of a model control group, and the difference is significant (P < 0.05).
Example 2
1. A traditional Chinese medicine compound composition with the effect of enhancing the immunity of organisms is prepared from the following raw materials in parts by weight:
20 parts of astragalus membranaceus, 10 parts of wolfberry fruit, 10 parts of radix ophiopogonis, 5 parts of schisandra chinensis, 10 parts of poria cocos, 4 parts of angelica sinensis, 7 parts of sea buckthorn and 10 parts of chrysanthemum morifolium.
2. The preparation process comprises the following steps: extracting 20 parts of radix astragali, 10 parts of fructus Lycii, 10 parts of radix Ophiopogonis, 5 parts of fructus Schisandrae chinensis, 10 parts of Poria, 4 parts of radix Angelicae sinensis, 7 parts of fructus Hippophae and 10 parts of flos Chrysanthemi with 10 times of 40% ethanol for 3 times (1 hr each time), mixing extractive solutions, concentrating at 80 deg.C under reduced pressure to obtain concentrated solution, and vacuum drying at 80 deg.C. The sample mainly contains 32% of total polysaccharides, 33% of total flavonoids and 8% of total phenolic acids.
3. Pharmacological experiments:
according to the test method of the pharmacological experiment in the above example 1, the compound Chinese medicinal composition for enhancing immunity in example 2 was tested for DTH-thickened hemolytic plaque number, serum hemolysin, carbon clearance phagocytosis index a, and phagocytosis rate of phagocytosed chicken red blood cells, as shown in table 4.
TABLE 4
Note: each dose group represents P <0.05 compared to the model control group.
From the above results, the difference between the model control group and the negative control group is significant (P <0.05), indicating that the modeling is successful; compared with the model control group, the differences of the medium and high dose groups are significant (P <0.05), which indicates that the medium and high dose groups can enhance the immune function of the mice.
Example 3
1. A traditional Chinese medicine compound composition with the effect of enhancing the immunity of organisms is prepared from the following raw materials in parts by weight:
10 parts of astragalus membranaceus, 5 parts of wolfberry fruit, 5 parts of radix ophiopogonis, 1 part of schisandra chinensis, 5 parts of poria cocos, 4 parts of angelica sinensis, 5 parts of sea buckthorn and 5 parts of chrysanthemum morifolium.
2. The preparation process comprises the following steps: extracting radix astragali 10 parts, fructus Lycii 5 parts, radix Ophiopogonis 5 parts, fructus Schisandrae 1 part, Poria 5 parts, radix Angelicae sinensis 4 parts, fructus Hippophae 5 parts, and flos Chrysanthemi 5 parts with 8 times of water for 3 times, each for 1.5 hr, mixing extractive solutions, concentrating at 80 deg.C under reduced pressure to obtain concentrated solution, and vacuum drying at 80 deg.C. The sample mainly contains 40% of total polysaccharides, 25% of total flavonoids and 8% of total phenolic acids.
3. Pharmacological experiments:
the number of plaques of hemolysis, serum hemolysin, carbon clearance phagocytosis index a, and phagocytosis rate of phagocytosed chicken red blood cells of the compound Chinese medicinal composition for enhancing immunity in example 3 were tested according to the testing method of the pharmacological experiment in example 1, as shown in table 5.
TABLE 5
Note: each dose group represents P <0.05 compared to the model control group.
From the above results, the difference between the model control group and the negative control group is significant (P <0.05), indicating that the modeling is successful; compared with the model control group, the differences of the medium and high dose groups are significant (P <0.05), which indicates that the medium and high dose groups can enhance the immune function of the mice.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents or improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (8)
1. A traditional Chinese medicine compound composition with immunity enhancing function is characterized by being prepared from the following raw materials in parts by weight:
10-40 parts of astragalus membranaceus, 5-20 parts of wolfberry fruits, 5-20 parts of radix ophiopogonis, 1-15 parts of schisandra chinensis, 5-20 parts of poria cocos, 2-15 parts of angelica sinensis, 2-20 parts of sea buckthorn and 5-20 parts of chrysanthemum morifolium.
2. The compound traditional Chinese medicine composition for enhancing immunity according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:
40 parts of astragalus membranaceus, 20 parts of wolfberry fruit, 20 parts of radix ophiopogonis, 10 parts of schisandra chinensis, 20 parts of poria cocos, 8 parts of angelica sinensis, 14 parts of sea buckthorn and 20 parts of chrysanthemum morifolium.
3. The compound traditional Chinese medicine composition for enhancing immunity according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:
20 parts of astragalus membranaceus, 10 parts of wolfberry fruit, 10 parts of radix ophiopogonis, 5 parts of schisandra chinensis, 10 parts of poria cocos, 4 parts of angelica sinensis, 7 parts of sea buckthorn and 10 parts of chrysanthemum morifolium.
4. The compound traditional Chinese medicine composition for enhancing immunity according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:
10 parts of astragalus membranaceus, 5 parts of wolfberry fruit, 5 parts of radix ophiopogonis, 1 part of schisandra chinensis, 5 parts of poria cocos, 4 parts of angelica sinensis, 5 parts of sea buckthorn and 5 parts of chrysanthemum morifolium.
5. The preparation method of the traditional Chinese medicine compound composition for enhancing immunity according to any one of claims 1 to 4, which is characterized by comprising the following steps:
(1) solvent extraction: refluxing or ultrasonic extracting with 5-15 times of water and 70% ethanol for 1-3 times, and each time for 0.5-2 h.
(2) Concentration: the concentration method comprises the steps of reduced pressure concentration at 50-80 ℃ and normal pressure concentration at 100 ℃.
(3) And (3) drying: drying modes include vacuum and spray drying.
6. The preparation method of the traditional Chinese medicine compound composition for enhancing immunity according to claim 5, which is characterized by comprising the following steps:
the preparation method comprises the following steps of taking astragalus, angelica, radix ophiopogonis, schisandra chinensis, wolfberry fruit, chrysanthemum, poria cocos and sea buckthorn according to the weight parts, adding 5-15 times of water or 10-70% ethanol of traditional Chinese medicines into the mixture, extracting for 1-3 times, 0.5-2 hours each time, combining extracting solutions, concentrating under reduced pressure or normal pressure, drying in vacuum or spray to obtain dry extract powder, and then preparing the dry extract powder into a medicine or health-care product together with a pharmaceutically acceptable carrier.
7. The preparation method of the traditional Chinese medicine compound composition for enhancing immunity according to claim 6, wherein the preparation is an oral preparation or an external preparation, and comprises tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, buccal tablets, chewable tablets, hard capsules, soft capsules, granules, pills, powder, dropping pills, oral liquid preparations, sprays, gels, ointments, cataplasms, emplastrums, liniments, lotions and coating agents.
8. The application of the traditional Chinese medicine compound composition for enhancing immunity according to any one of claims 1 to 4 in preparation of medicines or health products for enhancing immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664608.0A CN114306506A (en) | 2021-12-31 | 2021-12-31 | Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664608.0A CN114306506A (en) | 2021-12-31 | 2021-12-31 | Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114306506A true CN114306506A (en) | 2022-04-12 |
Family
ID=81021341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111664608.0A Pending CN114306506A (en) | 2021-12-31 | 2021-12-31 | Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114306506A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115152895A (en) * | 2022-06-13 | 2022-10-11 | 江苏护理职业学院 | Fermented astragalus membranaceus compound feed additive capable of promoting growth and resisting oxidation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102120A (en) * | 1993-10-30 | 1995-05-03 | 严天庆 | Body-building complete nutrient liquor (natural plant) |
| CN1116060A (en) * | 1994-08-04 | 1996-02-07 | 胡觉民 | Nutriment for improving health |
| CN1846763A (en) * | 2006-03-02 | 2006-10-18 | 浙江新光药业有限公司 | Medicine composition for treating coronary heart disease and its prepn process |
| CN104971214A (en) * | 2015-07-15 | 2015-10-14 | 李梦琦 | Traditional Chinese medicine composition with anti-fatigue effect |
| CN110974903A (en) * | 2019-12-25 | 2020-04-10 | 重庆希尔安药业有限公司 | Composition helpful for enhancing immunity and preparation method thereof |
| CN112891454A (en) * | 2019-12-04 | 2021-06-04 | 易小佳 | Tea bag capable of relieving fatigue |
-
2021
- 2021-12-31 CN CN202111664608.0A patent/CN114306506A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102120A (en) * | 1993-10-30 | 1995-05-03 | 严天庆 | Body-building complete nutrient liquor (natural plant) |
| CN1116060A (en) * | 1994-08-04 | 1996-02-07 | 胡觉民 | Nutriment for improving health |
| CN1846763A (en) * | 2006-03-02 | 2006-10-18 | 浙江新光药业有限公司 | Medicine composition for treating coronary heart disease and its prepn process |
| CN104971214A (en) * | 2015-07-15 | 2015-10-14 | 李梦琦 | Traditional Chinese medicine composition with anti-fatigue effect |
| CN112891454A (en) * | 2019-12-04 | 2021-06-04 | 易小佳 | Tea bag capable of relieving fatigue |
| CN110974903A (en) * | 2019-12-25 | 2020-04-10 | 重庆希尔安药业有限公司 | Composition helpful for enhancing immunity and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 杜佳林等: "增光片药效学实验研究", 《中成药》 * |
| 田玉英，赵丽娟: "放、热疗辅沙芪扶正口服液联合治疗恶性肿瘤疗效观察", 《肿瘤研究与临床》 * |
| 苗术等: "菊麦茶饮对衰老大鼠学习记忆能力和脑老化的影响", 《齐齐哈尔医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115152895A (en) * | 2022-06-13 | 2022-10-11 | 江苏护理职业学院 | Fermented astragalus membranaceus compound feed additive capable of promoting growth and resisting oxidation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10813961B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
| US10820615B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
| CN112057551A (en) | Composition with functions of nourishing yin and tonifying kidney and preparation method and application thereof | |
| CN110604800A (en) | Alcohol-dispelling liver-protecting plant beverage for abstinence of alcohol and preparation method thereof | |
| CN108713746A (en) | A kind of integration of drinking and medicinal herbs composition and its preparation method and application | |
| CN108041391A (en) | A kind of Black people join theanine drink and preparation method thereof | |
| CN114306506A (en) | Traditional Chinese medicine compound composition with effect of enhancing organism immunity and preparation method and application thereof | |
| CN105535425B (en) | A kind of Chinese medicine composition with strengthen immunity effect and preparation method thereof and purposes | |
| CN117256706A (en) | Ginseng extract imperial tea formula | |
| CN116173176A (en) | Anti-fatigue traditional Chinese medicine composition and preparation method thereof | |
| CN106075056A (en) | A kind of Ganoderma lucidum and preparation method improving immunity and improving gastrointestinal function | |
| CN111387394A (en) | Sea-buckthorn solid beverage for enhancing immunity and inhibiting tumors and preparation method thereof | |
| CN111298020B (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN113069505A (en) | Medicinal diet beverage for improving immunity and preparation method thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN110368469A (en) | Join glue stilbene particle drink | |
| CN1660398B (en) | Combination of medication for treating sleep disorder | |
| CN111346172B (en) | Pharmaceutical composition for improving immunity | |
| CN117244021B (en) | A Chinese medicinal composition extract for reducing blood sugar, blood lipid, blood pressure and uric acid, and its preparation method | |
| CN107753589B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN115607629B (en) | Traditional Chinese medicine composition with liver protecting and alcohol effect dispelling functions and preparation method thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
| CN115944700B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN113995791B (en) | Gynura procumbens compound medicine capable of benefiting qi, nourishing blood, and preventing and treating anemia and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220412 |
|
| RJ01 | Rejection of invention patent application after publication |